Assessment Status Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus
On 10 October 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of both insulin glargine 10mL vial (100 IU/ml) and 3mL pre-filled pen (100 IU/ml) for patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) through their inclusion in the Philippine National Formulary (PNF). In continue reading : Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus
Rituximab for the Treatment of Non-Hodgkin’s Lymphoma
Date of publication: 29 July 2022 Approval of the Secretary of health: 31 August 2022 Link to the Evidence summary HTAC Recommendation preview:
Insulin glargine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus
Preliminary Recommendation for the Inclusion of Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus in the PNF Link to the Evidence Summary: Evidence Summary on insulin glargine and detemir for type 1 and type 2 diabetes mellitus Link to appeals form here: https://hta.doh.gov.ph/topic-nomination/ (stakeholders may submit appeals to hta@doh.gov.ph until 11 August 2022.) Document Preview: